Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 410

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 410
---
<0.001

    CGIC Responders (number of patients assessed as “very much improved” or “much improved”(1)
    76 (37.6%)
     
    39 (19.6%)

    Chi-Square
    P<0.001

    Logistic regression (odds ratio [95% CI])(2)
    2.49 (1.58, 3.91)

    P<0.001

(1)        7-point scale rating patient’s overall improvement. Patient change is rated from “very much improved”, “much improved”, “minimally improved”, “no change”, “minimally worse”, “much worse” or “very much worse”.

(2)       Logistic regression models with treatment (SP-102 or placebo), site, and Pain Catastrophizing Scale group (<30 or ³30) as factors.

CI: confidence interval; ITT: intent-to-treat (randomized population)

    Time to Repeat Injection – ITT Population

    SP-102N=202
     
    Placebo N=199

    Number of patients with Repeat Injection of SP-102 (patients who received open-label SP-102 between 4 and 20 weeks after initial injection)
    134 (66.3%) 
     
    152 (76.4%)

    Number of censored patients(1)
    68 (33.7%)
     
    47 (23.6%)

    Chi-Square
    P=0.026

Time (days) to Repeat Injection

    N
     
    134 (66.3%)
     
    152 (76.4%)

    Mean (SD)
     
    67.0 (33.31)
     
    57.8 (31.69)

    Median
     
    57.5
     
    43.0

    Min, Max
     
    27, 143
     
    26, 148

    25th quantile (95% CI)(2)
     
    45 (43, 57)
     
    36 (34, 40)

    50th quantile (95% CI)(2)
     
    84 (71, 100)
     
    58 (50, 69)

    75th quantile (95% CI)(2)
     
    143 (